Esmolol Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	Bolus: 0.2-0.5 mg/kg IV over 1 minute, then continuous infusion at 25-200 mcg/kg/min, titrated to effect. Alternatively, start infusion at 50 mcg/kg/min and titrate.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) for acute control; use until oral beta-blocker can be initiated Notes: Titrate to heart rate and blood pressure; use lowest effective dose. Monitor ECG and blood pressure continuously.
Cat	IV	Bolus: 0.2-0.5 mg/kg IV over 1 minute, then continuous infusion at 10-50 mcg/kg/min, titrated to effect.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) for acute control; use until oral beta-blocker can be initiated Notes: Cats are sensitive to beta-blockers; start at low end of dose range. Monitor for bradycardia and hypotension.
Horse	IV	Bolus: 0.1-0.2 mg/kg IV over 1 minute, then continuous infusion at 25-100 mcg/kg/min, titrated to effect.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) for acute control Notes: Use with caution in horses with bronchoconstrictive disease. Monitor ECG and blood pressure.
Cattle	IV	Not established; extrapolate from other species: 0.2-0.5 mg/kg IV bolus, then 25-100 mcg/kg/min infusion.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) Notes: Extra-label use; monitor carefully.
Small Ruminants (sheep, goats)	IV	Not established; extrapolate from other species: 0.2-0.5 mg/kg IV bolus, then 25-100 mcg/kg/min infusion.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) Notes: Extra-label use; monitor carefully.
Rabbit	IV	Not established; extrapolate from other species: 0.2-0.5 mg/kg IV bolus, then 25-100 mcg/kg/min infusion.	Continuous infusion or intermittent boluses as needed	Duration: Short-term (minutes to hours) Notes: Extra-label use; monitor carefully.
Birds/Poultry	IV	Not established; use with caution and monitor closely.	Not established	Duration: Not established Notes: Limited data; use only if benefits outweigh risks.
Exotic/Other	IV	Not established; use with caution and monitor closely.	Not established	Duration: Not established Notes: Limited data; use only if benefits outweigh risks.

Clinical Indications & Species Uses

General Indications

Emergency management of acute tachyarrhythmias (SVT, atrial fibrillation) and hypertensive crises
Control of heart rate and blood pressure during anesthesia or surgery

Dog (Canine)

Supraventricular tachycardia (SVT)
Atrial fibrillation/flutter with rapid ventricular response
Hypertensive emergencies
Perioperative tachycardia and hypertension
Hypertrophic cardiomyopathy (adjunctive therapy)

Cat (Feline)

Supraventricular tachycardia (SVT)
Hypertrophic cardiomyopathy (HCM) with dynamic outflow tract obstruction
Hypertensive emergencies
Perioperative tachycardia

Horse (Equine)

Supraventricular tachycardia (SVT)
Atrial fibrillation (rate control)
Perioperative tachycardia and hypertension

Pharmacology & Mechanism of Action

Drug Class: Beta-adrenergic receptor antagonist (beta-blocker) | Pharmacological Group: Antiarrhythmic agent (Class II), antihypertensive

Mechanism of Action: Esmolol is a cardioselective beta-1 adrenergic receptor antagonist that competitively blocks the effects of catecholamines (epinephrine, norepinephrine) at beta-1 receptors, primarily located in cardiac tissue. This results in a decrease in heart rate, myocardial contractility, and cardiac output, leading to reduced myocardial oxygen demand. At therapeutic doses, it has minimal effect on beta-2 receptors (bronchial and vascular smooth muscle). Its ultra-short duration of action is due to rapid hydrolysis by red blood cell esterases.

Pharmacodynamics: Esmolol produces a rapid and titratable beta-blockade. It decreases sinus node automaticity, slows atrioventricular (AV) conduction, and prolongs AV nodal refractoriness. It reduces heart rate and blood pressure, especially during exercise or stress. It has a negative inotropic effect, which can be beneficial in conditions like hypertrophic cardiomyopathy or tachycardia-induced myocardial ischemia. The onset of action is within 2-5 minutes after IV administration, and effects dissipate within 10-20 minutes after discontinuation due to rapid metabolism.

⚡ Pharmacokinetics Summary

Absorption: Esmolol is administered intravenously; oral absorption is not applicable. Onset of action is rapid (within 2-5 minutes) after IV bolus or infusion.

Distribution: Esmolol is widely distributed. The volume of distribution is approximately 3.4 L/kg in humans. It crosses the placenta and is distributed into milk. Protein binding is approximately 55%.

Metabolism: Esmolol is rapidly metabolized by esterases in red blood cells (not plasma cholinesterases) to an inactive acid metabolite and methanol. Metabolism is independent of hepatic and renal function.

Excretion: The inactive metabolite is excreted renally. The elimination half-life is approximately 9 minutes in humans; in dogs, it is about 10-15 minutes. Clearance is high (about 20 mL/kg/min in humans).

Half-Life: Approximately 9 minutes in humans; 10-15 minutes in dogs; similar in cats.

Bioavailability: Not applicable (IV only).

Protein Binding: Approximately 55% (primarily to albumin).

Available Formulations & Strengths

Injectable Solution 10 mg/mL (2 mL and 10 mL vials) (IV)

Premixed Infusion 10 mg/mL in 100 mL bags (for IV infusion) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to esmolol or any beta-blocker
Severe bradycardia (heart rate < 60 bpm in dogs, < 100 bpm in cats, depending on species)
Second- or third-degree atrioventricular block without a pacemaker
Cardiogenic shock or decompensated heart failure
Severe hypotension (systolic blood pressure < 80 mmHg)
Uncompensated congestive heart failure
Concurrent use of MAO inhibitors (except MAO-B inhibitors) or IV calcium channel blockers (e.g., verapamil, diltiazem) due to risk of severe hypotension and bradycardia

Warnings & Clinical Precautions:

Use with caution in animals with bronchospastic disease (e.g., asthma, COPD) as beta-1 selectivity is dose-dependent; higher doses may affect beta-2 receptors.
Use with caution in animals with diabetes mellitus; beta-blockers may mask signs of hypoglycemia (tachycardia, tremors).
Use with caution in animals with peripheral vascular disease (e.g., Raynaud's phenomenon) as beta-blockade can exacerbate symptoms.
Use with caution in animals with renal or hepatic impairment; although metabolism is independent of these organs, the inactive metabolite may accumulate in renal failure.
Do not stop abruptly; sudden withdrawal can exacerbate angina or cause rebound tachycardia. Taper if possible.
Monitor heart rate, blood pressure, and ECG continuously during administration.
In animals with hypertrophic cardiomyopathy, use cautiously as beta-blockade may worsen outflow obstruction in some cases.
Esmolol is for IV use only; extravasation can cause tissue necrosis.
Use in pregnant or lactating animals only if clearly needed; safety not established.

Adverse Effects & Reactions

Common:

Hypotension
Bradycardia
Injection site reactions (pain, erythema)
Nausea (in humans; may occur in animals)

Serious / Severe:

Severe bradycardia
Heart block (AV block)
Cardiac arrest
Bronchospasm (in animals with reactive airway disease)
Pulmonary edema (in animals with compromised cardiac function)
Hypotension leading to shock

Rare:

Thrombocytopenia
Seizures (in overdose)
Hyperkalemia
Hypoglycemia (especially in neonates or insulin-dependent diabetics)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other beta-blockers (e.g., propranolol, atenolol)	Additive beta-blockade, increased risk of bradycardia and hypotension.	High
Calcium channel blockers (verapamil, diltiazem)	Additive negative inotropic and chronotropic effects; risk of severe bradycardia, hypotension, and heart block.	High
Digoxin	Additive negative chronotropic effects; increased risk of bradycardia and AV block.	Moderate
Amiodarone	Additive effects on heart rate and conduction; increased risk of bradycardia and QT prolongation.	Moderate
Sympathomimetics (e.g., epinephrine, dobutamine)	Antagonism of beta-adrenergic effects; may reduce inotropic and chronotropic response.	Moderate
Insulin or oral hypoglycemics	Beta-blockade may mask symptoms of hypoglycemia (tachycardia, tremors) and prolong hypoglycemic episodes.	Moderate
NSAIDs (e.g., indomethacin)	May reduce antihypertensive effect of beta-blockers.	Mild
Cimetidine	May increase esmolol levels (though metabolism is via esterases, not CYP450, so interaction is minimal).	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe bradycardia
Hypotension
AV block
Cardiac arrest
Bronchospasm
Hypoglycemia
Seizures (in severe cases)

Emergency Treatment Protocol: Discontinue esmolol immediately. Administer atropine (0.04 mg/kg IV) for bradycardia. For severe hypotension or bradycardia unresponsive to atropine, consider glucagon (50-150 mcg/kg IV bolus, followed by infusion) to support cardiac function. In refractory cases, use beta-adrenergic agonists (e.g., dobutamine, isoproterenol) with caution. Provide supportive care including IV fluids, oxygen, and cardiac monitoring. Hemodialysis is not effective due to rapid metabolism.

Food Animal Withdrawal Times

Esmolol is not approved for use in food animals. Withdrawal times are not established. If used off-label in food animals, consult with a veterinary pharmacologist and follow appropriate withdrawal periods (e.g., at least 7 days for meat and 72 hours for milk, but this is not evidence-based).

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Do not freeze. Protect from excessive heat. Use diluted solutions within 24 hours if stored at room temperature; discard unused portions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Brevibloc).

Extra-Label (Off-Label) Use: Esmolol is not FDA-approved for veterinary use; use in animals is extra-label. In the US, extra-label use is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) for non-food animals. For food animals, extra-label use is prohibited if an approved animal drug exists that is effective, but since no approved beta-blocker for food animals exists, it may be used with a valid veterinary-client-patient relationship and appropriate withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Esmolol is an ultra-short-acting beta-1 selective blocker that is ideal for emergency management of tachyarrhythmias and hypertensive crises in veterinary patients. Its rapid onset and offset allow for precise titration and quick reversal if adverse effects occur. It is particularly useful in critical care settings, such as during anesthesia or in patients with unstable hemodynamics. Because it is administered intravenously, it is not suitable for long-term outpatient therapy; transition to an oral beta-blocker (e.g., atenolol) should be initiated once the patient is stable. Esmolol should be used with caution in animals with bronchospastic disease, heart failure, or diabetes. Continuous monitoring of ECG, blood pressure, and heart rate is essential. In cats, lower doses are recommended due to increased sensitivity. For food animals, extra-label use requires careful consideration of withdrawal times and regulatory compliance.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)